Dr. Delmas has received consulting fees and/or honoraria from the following pharmaceutical companies: Amgen, Eli Lilly, GlaxoSmithKline, Novartis, Nycomed, Organon, Pfizer, Proctor & Gamble, Sanofi-Aventis, Servier, Wyeth (less than $10,000 each), and Roche (more than $10,000). Drs. Reginster, Civitelli, and Reid have received consulting fees and/or honoraria (less than $10,000 each) from Roche and GlaxoSmithKline.
Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study
Article first published online: 25 MAY 2006
Copyright © 2006 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 54, Issue 6, pages 1838–1846, June 2006
How to Cite
Delmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J.-Y., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., Bolognese, M., Hughes, C., Masanauskaite, D., Ward, P., Sambrook, P. and Reid, D. M. (2006), Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis & Rheumatism, 54: 1838–1846. doi: 10.1002/art.21918
- Issue published online: 25 MAY 2006
- Article first published online: 25 MAY 2006
- Manuscript Accepted: 15 MAR 2006
- Manuscript Received: 13 JUL 2005
- F. Hoffmann-La Roche Ltd, Basel, Switzerland
- GlaxoSmithKline, Brentford, UK
Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis.
In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 mg every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55–80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2−L4] bone mineral density [BMD] T score less than −2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability.
At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P < 0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function.
As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.